Article summary
Texas Ibogaine Research Corporation will receive exclusive US rights to PsyLabs’ ibogaine know-how, supply and wholesale distribution, while PsyLabs retains rights elsewhere. The arrangement includes up to approximately US$1.3 million in development and regulatory milestones, royalties and margin sharing, subject to a definitive agreement by 30 November 2026.
Continue to the original publication for the complete article.